Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · breast-umap@18

SRR1313092

— · B

2247e275-f06c-53d7-bbc3-4d9bfc45415e

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
B
subtype
B

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • OXIDATIVE_PHOSPHORYLATION+0.390
  • MYC_TARGETS_V2+0.370
  • MYC_TARGETS_V1+0.280
  • ADIPOGENESIS+0.270
  • BILE_ACID_METABOLISM+0.270
  • FATTY_ACID_METABOLISM+0.250
  • PEROXISOME+0.220
  • PANCREAS_BETA_CELLS+0.190
  • ESTROGEN_RESPONSE_EARLY+0.160
  • XENOBIOTIC_METABOLISM+0.130

Top 10 suppressed

  • TNFA_SIGNALING_VIA_NFKB-0.470
  • WNT_BETA_CATENIN_SIGNALING-0.460
  • NOTCH_SIGNALING-0.410
  • TGF_BETA_SIGNALING-0.410
  • INFLAMMATORY_RESPONSE-0.400
  • ANGIOGENESIS-0.370
  • HEDGEHOG_SIGNALING-0.370
  • IL6_JAK_STAT3_SIGNALING-0.360
  • EPITHELIAL_MESENCHYMAL_TRANSITION-0.340
  • MITOTIC_SPINDLE-0.340

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

9 twins match this tumor's tissue · 1 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1SRR8518209
breast-umap@18
—C0.917
2TCGA-LL-A6FP-01A-11R-A31O-07
breast-umap@18
—B0.872
3TCGA-55-6972-01A-11R-1949-07
lung-landscapes@6
—cohortA20.872
4C3L-00140
lung-landscapes@6
—cohortA20.868
520070010.LumB
breast-umap@18
—B0.865
6TCGA-GU-A763-01A-11R-A32O-07
bladder-landscape@3
——0.863
7TCGA-TN-A7HJ-01A-12R-A34R-07
head-neck@1
——0.856
8SRR10900578
melanoma-umap@29
——0.854
920110028.LumB
breast-umap@18
—B0.852
10MDT-AP-1302
medullo-epn-umap@date-based
MedMedulloblastoma0.852

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 17 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
OXIDATIVE_PHOSPHORYLATION0.390Remibrutinib— uncovered
MYC_TARGETS_V20.370Idelalisib— uncovered
MYC_TARGETS_V10.280Inavolisib— uncovered
ADIPOGENESIS0.270Inavolisib— uncovered
BILE_ACID_METABOLISM0.270Inavolisib— uncovered
FATTY_ACID_METABOLISM0.250Inavolisib— uncovered
PEROXISOME0.220Idelalisib— uncovered
PANCREAS_BETA_CELLS0.190Cobimetinib— uncovered
ESTROGEN_RESPONSE_EARLY0.160Inavolisib— uncovered
XENOBIOTIC_METABOLISM0.130Inavolisib— uncovered
ESTROGEN_RESPONSE_LATE0.100Idelalisib— uncovered
DNA_REPAIR0.090Idelalisib— uncovered
REACTIVE_OXYGEN_SPECIES_PATHWAY0.090Inavolisib— uncovered
CHOLESTEROL_HOMEOSTASIS0.070Remibrutinib— uncovered
SPERMATOGENESIS0.070Inavolisib— uncovered
PROTEIN_SECRETION0.030Remibrutinib— uncovered
KRAS_SIGNALING_DN0.010Remibrutinib— uncovered